MYELOMATCH Screening Trial
Phase 2
2,000
about 4.9 years
18+
335 sites in AL, AR, AZ +41
What this study is about
This trial is testing a screening tool to help people with leukemia or myelodysplastic syndrome get into clinical trials. It involves testing bone marrow and blood for certain markers that can guide treatment decisions. This will determine if patients are eligible for a specific treatment trial or standard of care treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Best Practice
- 2.Receive Total-Body Irradiation
- 3.Take Azacitidine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
azacitidine, busulfan, cytarabine, Antineoplastic Agent [TC] (DNA Polymerase Inhibitors), decitabine, enasidenib, Blood Products/Modifiers/Volume Expanders, fludarabine
injection, subcutaneous, intravenous, injection (Injection), oral (Oral Tablet), oral (Oral Capsule), oral
Secondary: Adverse events, Performance status
biopsy, diagnostic, imaging, radiation
Oncology